The Food and Drug Administration said it granted accelerated approval to Takeda Pharmaceuticals’ ponatinib with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TAK:
- Protagonist closes rusfertide license, collaboration agreement with Takeda
- Takeda announces results from Phase 2 study of mezagitamab as antibody for ITP
- Takeda price target raised to $14.30 from $13.70 at JPMorgan
- Takeda, Biological E. Limited collaborate to accelerate access to Dengue vaccine
- FDA approvesTakeda’s Eohilia for eosinophilic esophagitis treatment
